ADMA Biologics Inc vs Alphabet Inc Class A — how do they compare? ADMA Biologics Inc trades at $9.95 (market cap $2.22B), while Alphabet Inc Class A trades at $342.06 (market cap $4.20T). The key difference: Alphabet Inc Class A is far larger — about 1891.9× ADMA Biologics Inc's market cap, and Alphabet Inc Class A pays a 0.26% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GOOGL | |
|---|---|---|
Market Cap | $2.22B | $4.20T |
Sector | Health | Media |
52-Week High | $20.38 | $402.62 |
52-Week Low | $7.60 | $199.32 |
Enterprise Value | $2.29B | $4.09T |
Dividend Yield | — | 0.26% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Alphabet (GOOGL) trades at $357.52, up 0.91% today, with a bullish technical signal from moving averages and strong support at $354. The stock shows robust fundamentals, with revenue growing from $350.0B in 2024 to $402.8B in 2025 (SEC filings, 2025), net income margin expanding to 32.8%, and consistent earnings beats. Recent news highlights AI-driven growth opportunities, including partnerships and YouTube price increases (Reuters, 2026-04-10).
Outlook remains positive with an 85% analyst buy rating and $426.28 consensus price target (MarketBeat, 2026-04-11), though risks include antitrust scrutiny and tech sector volatility. Earnings growth and AI integration are key catalysts for upside, while competition and regulatory pressures warrant monitoring.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →